Sotrovimab Resistance and Viral Persistence After Treatment of Immunocompromised Patients Infected With the Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant

Research output: Contribution to journalArticleAcademicpeer-review

25 Citations (Scopus)
22 Downloads (Pure)

Abstract

Viral evolution was evaluated in 47 immunocompromised patients treated with sotrovimab. Sequencing of SARS-CoV-2 following therapy was successful in 16. Mutations associated with sotrovimab resistance were documented in 6; viral replication continued after 30 days in 5. Combination antibody therapy may be required to avoid acquired resistance in immunocompromised patients.

Original languageEnglish
Pages (from-to)e507-e509
JournalClinical infectious diseases : an official publication of the Infectious Diseases Society of America
Volume76
Issue number3
DOIs
Publication statusPublished - 1 Feb 2023

Bibliographical note

Publisher Copyright:
© 2022 The Author(s). Published by Oxford University Press on behalf of Infectious Diseases Society of America.

Fingerprint

Dive into the research topics of 'Sotrovimab Resistance and Viral Persistence After Treatment of Immunocompromised Patients Infected With the Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant'. Together they form a unique fingerprint.

Cite this